National Institutes of Health

Description

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) is inviting applications to form the Acquired Resistance to Therapy Network (ARTNet). The ARTNet FOA is a reissuance that builds upon the Drug Resistance and Sensitivity Network (DRSN, RFA-CA-17-009) to focus study on the mechanistic basis of acquired resistance to cancer therapies and disease recurrence. Central to the ARTNets structural organization is team science approaches that iteratively bridge basic, pre-clinical, and translational research along the tumor-microenvironment continuum to inform new strategies that can be better translated to overcome significant challenges in acquired resistance to cancer therapies. This FOA will be published in parallel with a companion FOA titled Coordinating and Data Management Center (CDMC) for Acquired Resistance to Therapy Network (ARTNet; U24 Clinical Trial Not Allowed).

Who can apply

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities / Indian housing authorities
• Native American tribal organizations (other than Federally recognized)
• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses
• Others

Contact

NIH OER Webmaster<br/>OERWebmaster03@od.nih.gov
OERWebmaster03@od.nih.gov